Chronic hepatitis B virus (HBV) infection affects about 296 million people worldwide and is
the leading aetiology of cirrhosis and liver cancer globally. Major medical complications also …

The management of viral hepatitis in the setting of pregnancy requires special consideration.
There are five liver-specific viruses (hepatitis A, B, C, D, E), each with unique epidemiology …

Background Prevention of mother-to-child transmission (MTCT) of hepatitis B virus (HBV)
involves neonatal immunoprophylaxis, with a birth dose of hepatitis B vaccine and immune …

Abstract In 2016 the World Health Organization set the goal of eliminating hepatitis B
globally by 2030. Horizontal transmission has been greatly reduced in most countries by …

Liver diseases in pregnancy comprise both gestational liver disorders and acute and chronic
hepatic disorders occurring coincidentally in pregnancy. Whether related to pregnancy or …

In 2016, WHO member states at the World Health Assembly adopted a Global Health Sector
Strategy that included a policy of eliminating viral hepatitis. Clear targets were established to …

Hepatitis B virus (HBV) infection still remains a major public health issue in the Asia–Pacific
region. Most of the burden of HBV-related disease results from infections acquired in infancy …

Summary Background In sub-Saharan Africa, administration of hepatitis B virus (HBV) birth-
dose vaccines remains suboptimal. Evidence is scarce on whether African countries should …

Viral hepatitis results in 1.4 million deaths annually. The World Health Organization (WHO)
set an ambitious target to eliminate viral hepatitis by 2030, but significant challenges remain …

Background In 2020, WHO recommended the addition of peripartum antiviral prophylaxis
(PAP) to hepatitis B birth dose vaccination (HepB-BD) and hepatitis B infant vaccination …